Post-menopausal women in England are among the most heavily medicated patient groups in primary care. A woman aged 65 or older is likely to be taking five or more regular medicines — the clinical threshold for polypharmacy — according to NHS England's medicines optimisation dashboard.
New government plans to improve healthcare for women and girls, announced on 15 April 2026, acknowledge that women's health concerns are still frequently overlooked. Polypharmacy in older women is a case in point: it is common, clinically significant, and often invisible until an adverse event forces a review.
Why older women carry a higher polypharmacy burden
Several factors converge after menopause. Hormone replacement therapy, osteoporosis prophylaxis (bisphosphonates, calcium, vitamin D), cardiovascular risk management (statins, antihypertensives), pain relief for musculoskeletal conditions and mental health prescriptions each add to the daily pill count. Women also live longer on average than men, meaning more years of cumulative prescribing.
NHS Digital data consistently shows that women aged 65–84 receive more prescription items per head than men of the same age. The gap widens further after 85, when co-morbidity and frailty accelerate.
What polypharmacy looks like in practice
Polypharmacy is not inherently harmful — a patient with well-controlled hypertension, type 2 diabetes and osteoporosis may genuinely need all of their medicines. The concern is inappropriate polypharmacy: medicines that are no longer indicated, that duplicate each other's effects, or that interact in ways that cause side effects mistaken for new conditions.
Common examples in older women include:
| Combination | Risk |
|---|---|
| Bisphosphonate + calcium carbonate taken together | Calcium impairs bisphosphonate absorption; must be separated by at least 30 minutes |
| SSRI + alendronate | Both increase fracture risk; combined effect may outweigh benefit in very elderly patients |
| Statin + amlodipine at high dose | Interaction raises statin exposure; dose ceiling applies |
| PPI long-term + calcium supplement | Long-term PPI use may reduce calcium absorption, potentially undermining the supplement |
| Multiple anticholinergic medicines | Cumulative anticholinergic burden linked to confusion, falls and cognitive decline |
The structured medication review
Since 2020, NHS England has funded structured medication reviews (SMRs) in primary care, delivered by clinical pharmacists working in Primary Care Networks (PCNs). These reviews are specifically targeted at patients with polypharmacy, those in care homes, and those on high-risk medicines.
A structured medication review typically involves:
- A face-to-face or telephone consultation lasting 20–40 minutes
- A full medicines reconciliation — checking what the patient actually takes versus what is prescribed
- Identification of medicines that may no longer be needed, interactions, and adherence issues
- Agreement with the patient on any changes, with GP sign-off where required
Community pharmacists also deliver medicines optimisation through the New Medicine Service (NMS) and informal counter consultations. The NMS targets patients starting a new medicine for a long-term condition, offering follow-up at 7 and 14 days to catch early problems.
What community pharmacy adds
Community pharmacists see patients more frequently than GPs — often monthly for repeat dispensing. That regular contact creates opportunities to spot:
- Medicines the patient has stopped taking without telling the GP
- New over-the-counter purchases that interact with prescribed medicines (e.g. ibuprofen with warfarin)
- Dosette box discrepancies where a medicine has been discontinued but remains in the tray
- Side effects the patient attributes to ageing rather than medication
PharmSee tracks over 1,742 active pharmacy vacancies across England, with 491 NHS roles including PCN clinical pharmacist positions responsible for medication reviews. The workforce pipeline for this service is growing, though demand continues to outstrip supply in many regions.
Deprescribing: the conversation that matters
Deprescribing — the planned, supervised withdrawal of medicines that are no longer appropriate — is the practical outcome of a good polypharmacy review. It is not about taking medicines away; it is about aligning the prescription with the patient's current clinical picture and preferences.
For older women, common deprescribing conversations include:
- Stopping long-term PPIs where the original indication (e.g. NSAID gastroprotection) no longer applies
- Reviewing bisphosphonate duration — NICE recommends reassessment after 5 years of oral treatment
- Tapering benzodiazepines or Z-drugs prescribed for insomnia, where risks of falls and cognitive impairment increase with age
- Stepping down antihypertensives in frail patients where tight blood pressure control may cause postural hypotension
The evidence supporting deprescribing is growing. A 2023 Cochrane review found that structured deprescribing interventions in older adults reduced the number of potentially inappropriate medicines without increasing adverse outcomes.
How to access a medication review
Any patient — or their carer — can request a medication review through their GP practice. Patients registered with a PCN that employs a clinical pharmacist may be proactively invited. Community pharmacists can also initiate an informal review during a dispensing consultation and refer to the GP or PCN pharmacist for formal changes.
To find pharmacies offering NHS services near you, use PharmSee's pharmacy finder. For information on pharmacist roles in medication reviews, see the salary and career data section.
Caveats
Polypharmacy prevalence figures are drawn from NHS Digital prescribing data and NHS England's medicines optimisation programme. Individual patient data is not available through PharmSee. The 1,742 vacancy figure reflects PharmSee's tracking of 11 public job sources as of mid-April 2026 and does not capture all pharmacy roles (see our data sources page for methodology).
Sources: NHS England Medicines Optimisation, NHS Digital Prescribing Data, NICE Guidelines [NG5] Medicines Optimisation, Cochrane Systematic Reviews, PharmSee vacancy database (April 2026).